Agency: European Commission | Branch: FP7 | Program: BSG-SME | Phase: SME-2013-1 | Award Amount: 1.72M | Year: 2013
The aim of TA101GOCLIN Project is to take TA101 into the clinical stage of development for rheumatoid arthritis and prepare the product for a novel mode of administration in the market of biologic therapeutics. Rheumatoid Arthritis is still today a debilitating disease with an unmet medical need for effective and reasonably priced treatments despite much effort to cure or control the disease. TA101 is a small domain antibody that is being developed for the treatment of rheumatoid arthritis and has passed through preclinical efficacy studies with much success. TA101 will now undergo an upscaling process of production to enter clinical trials. TA101GOCLIN project is within the scope of the clinical development of TA101 and is aimed at providing safety data in humans through a clinical trial of Phase Ia and Ib. Concomitantly, TA101GOCLIN will develop a novel mode of administration for TA101 to be used after project end. This will provide a major competitive advantage for the product already during development stages. The innovative administration will use microneedle patches, a new method that allows the autonomous administration of the drug through the skin without the pain of conventional injections. To achieve the above mentioned objectives, TA101GOCLIN gathered three competitive SMEs from Portugal, Belgium and The Netherlands. TechnoPhage, Q-Biologicals and MyLife Technologies, respectively, will be responsible for developing the clinical data of Phase I for TA101, develop an upscale method for production of the drug, and develop the microneedle device for administration of TA101. Overall, TA101GOCLIN holds the promise that an innovative product for the treatment of Rheumatoid Arthritis will enter the clinical phases of development with the confidence that the technologies that are at its base will create a new solution for the patients, with the major benefits of efficacy, safety, convenience and affordability.
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2014 | Award Amount: 1.39M | Year: 2015
INPACT aims at the pre-clinical development of innovative drugs and drug formulations against selected cancers (eg prostate cancer) and pathogenic bacteria (eg S. aureus). The INPACT consortium allies the expertise of both academic and industrial R&D partners that contribute with their own unique technologies to achieve new drugs that are only possible to develop in an integrative effort. Academic partners have unique knowledge and technologies on supercharged viral proteins-derived cell-penetrating peptides (eg from Dengue virus) and ultra-resistant cyclic peptides that may be transferred to the industrial partners, which in turn have specialized proprietary technologies on anticancer and/or peptide drugs technologies. The judicious exchange of knowledge among partners will lead to new resistant peptides for trans-barrier delivery of drugs (eg cyclic peptide-drug chimeras) and bacterial killing (both planktonic and biofilms). INPACT includes four leading academic partners (from Portugal, Spain, Australia, and Brazil) and three consolidated biotech SMEs (one from Portugal and two Spain). In addition to the R&D project itself, INPACT involves at the highest possible level a top business school in Europe (IESE, Barcelona, Spain), a consolidated media partner specialised in science communication (Ciencia Hoje, Rio de Janeiro, Brazil) and experts in international science funding from one of the top US universities (University of Stanford). The consortium will be the perfect environment for young researchers to acquire knowledge and skills in science, technology, entrepreneurship, business, and communication so they can pro-actively tailor their career path in a life-long learning perspective. This is a contribution towards the advancement of Europe through the use of research and education for societal development and economic growth.
Tecnifar Industria Tecnica Farmaceutica S.A. and Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa | Date: 2010-02-05
The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.